Toll Free: 1-888-928-9744

Chroma Therapeutics Ltd. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 34 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Chroma Therapeutics Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Chroma Therapeutics Ltd. - Product Pipeline Review - 2014', provides an overview of the Chroma Therapeutics Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Chroma Therapeutics Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Chroma Therapeutics Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Chroma Therapeutics Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Chroma Therapeutics Ltd.'s pipeline products

Reasons to buy

- Evaluate Chroma Therapeutics Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Chroma Therapeutics Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Chroma Therapeutics Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Chroma Therapeutics Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Chroma Therapeutics Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Chroma Therapeutics Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Chroma Therapeutics Ltd. Snapshot 5
Chroma Therapeutics Ltd. Overview 5
Key Information 5
Key Facts 5
Chroma Therapeutics Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
Chroma Therapeutics Ltd. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Chroma Therapeutics Ltd. - Pipeline Products Glance 13
Chroma Therapeutics Ltd. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Chroma Therapeutics Ltd. - Early Stage Pipeline Products 15
Discovery Products/Combination Treatment Modalities 15
Chroma Therapeutics Ltd. - Drug Profiles 16
tosedostat 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
CHR-3996 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
tefinostat 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CHR-5250 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CHR-5623 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
CHR-6576 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecules for Inflammation 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecules to Antagonize CSF-1 Receptor for Oncology 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Chroma Therapeutics Ltd. - Pipeline Analysis 25
Chroma Therapeutics Ltd. - Pipeline Products by Target 25
Chroma Therapeutics Ltd. - Pipeline Products by Route of Administration 26
Chroma Therapeutics Ltd. - Pipeline Products by Molecule Type 27
Chroma Therapeutics Ltd. - Pipeline Products by Mechanism of Action 28
Chroma Therapeutics Ltd. - Recent Pipeline Updates 29
Chroma Therapeutics Ltd. - Dormant Projects 31
Chroma Therapeutics Ltd. - Locations And Subsidiaries 32
Head Office 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34
List of Tables
Chroma Therapeutics Ltd., Key Information 5
Chroma Therapeutics Ltd., Key Facts 5
Chroma Therapeutics Ltd. - Pipeline by Indication, 2014 8
Chroma Therapeutics Ltd. - Pipeline by Stage of Development, 2014 9
Chroma Therapeutics Ltd. - Monotherapy Products in Pipeline, 2014 10
Chroma Therapeutics Ltd. - Out-Licensed Products in Pipeline, 2014 11
Chroma Therapeutics Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
Chroma Therapeutics Ltd. - Phase II, 2014 13
Chroma Therapeutics Ltd. - Phase I, 2014 14
Chroma Therapeutics Ltd. - Discovery, 2014 15
Chroma Therapeutics Ltd. - Pipeline by Target, 2014 25
Chroma Therapeutics Ltd. - Pipeline by Route of Administration, 2014 26
Chroma Therapeutics Ltd. - Pipeline by Molecule Type, 2014 27
Chroma Therapeutics Ltd. - Pipeline Products by Mechanism of Action, 2014 28
Chroma Therapeutics Ltd. - Recent Pipeline Updates, 2014 29
Chroma Therapeutics Ltd. - Dormant Developmental Projects,2014 31 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify